# FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

> **NCT02485834** · PHASE2 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 5 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Gastric Adenocarcinoma
- Gastric Cancer

## Interventions

- **PROCEDURE:** FDG-PET
- **PROCEDURE:** surgery
- **DRUG:** 5-FU
- **DRUG:** capecitabine
- **DRUG:** docetaxel
- **DRUG:** Irinotecan
- **RADIATION:** 3D-CRT
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT02485834
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-12
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2025-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485834, "FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02485834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*